N@N

Eurand N.V.: Eurand Announces Conference Call on First Quarter 2009 Financial Results

_{//health-fitness.news-articles.net/content/2009/ .. all-on-first-quarter-2009-financial-results.html}
^{Published in Health and Fitness on Wednesday, April 15th 2009 at 7:17 GMT, Last Modified on 2009-04-15 07:17:34 by Market Wire}  

AMSTERDAM, THE NETHERLANDS--(Marketwire - April 15, 2009) - Eurand N.V. (NASDAQ: [ EURX ]), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, will hold a conference call on Thursday, May 7, 2009 at 8:30 a.m. ET to discuss its first quarter 2009 financial results. Gearóid Faherty, Chairman and Chief Executive Officer, and Mario Crovetto, Chief Financial Officer, will host the call.

The schedule is as follows:

 7:00 a.m. ET: First quarter 2009 financial results released 8:20 a.m. ET: Dial in to participate in the conference call: -- U.S. Participants dial 1-877-407-9039 -- International Participants dial + 1-201-689-8470 8:30 a.m. ET: Conference call begins 

Call Replay: A replay of the call will be available from 11:30 a.m. ET on May 7, 2009 until June 7, 2009. The Account Number is: 3055; Conference ID Number: 320431.

 -- U.S. Participants dial 1-877-660-6853 -- International Participants dial + 1-201-612-7415 

Webcast: A live webcast of the call also will be available from the Investor Relations section of the corporate web site at [ www.eurand.com ]. Following the live webcast, the archived version of the call will be available at the same URL until June 7, 2009.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had four products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at [ www.eurand.com ].